Visalytics
Visalytics
approved EB-2 (NIW)

Researcher 5

Chemistry · China · 2025-08-18

Processing Time
41 days
Decision Date
2025-08-18
Location
Minnesota
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop effective protease inhibitors that achieve stronger enrichment in the brain to reduce tau-induced neurotoxicity. This work specifically targets the progression of Alzheimer’s disease and related dementias through the design of small-molecule inhibitors. The research aims to address the medical and social challenges posed by the growing prevalence of dementia in aging populations.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The research addresses the pressing medical challenge of Alzheimer's disease, which impacts millions of Americans and represents a significant public health priority.

2 Well Positioned to Advance the Endeavor Met

The petitioner's Ph.D., 11 publications, 150 citations, and patent demonstrate a record of success and influence in medicinal chemistry.

3 Balance of Factors Met

The petitioner's unique expertise in developing brain-enriched protease inhibitors makes it beneficial to waive the labor certification requirement to advance U.S. biomedical innovation.

Why This Petition Was Approved

The petition was approved based on the petitioner's Ph.D. in chemistry and a record of 11 peer-reviewed journal articles with 150 citations. Evidence included one granted patent, four completed peer reviews for authoritative journals, and support from field experts. The case successfully satisfied all three prongs of the Dhanasar framework, demonstrating the national importance of treating neurodegenerative diseases.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Patents
Reference Letters Independent
Conference Presentations
Judging Experience
Original Contributions
Government Alignment

Similar Cases

Scientist

Biotechnology · India

WeGreened EB-2 (NIW) approved
New York 106 days 2023-01-28
The petitioner proposes to elucidate the genetic mechanisms underlying neurodegenerative diseases using expertise in biochemistry, genetics, and molecular biology. The work focuses on identifying new biological targets for the treatment of Alzheimer’s disease, Parkinson’s disease, and other dementias to provide insights into neuronal degeneration.
View Case

Doctor

Biotechnology · China

WeGreened EB-2 (NIW) rfe approved
484 days 2025-10-31
The petitioner proposes to continue critical research using cellular and molecular techniques to elucidate the mechanisms of neurodegenerative diseases. This work aims to facilitate the development of new and improved prognostic and diagnostic tools for medical applications.
View Case

Scientist

Research and Development · China

WeGreened EB-2 (NIW) approved
California 474 days 2025-03-07
The petitioner proposes to continue research into the cellular and molecular mechanisms of learning and memory to identify new therapeutic targets for neurodegenerative conditions like Alzheimer’s and Parkinson’s disease. The work involves identifying specific neuronal dynamics and molecular mechanisms to decrease mortality and reduce national healthcare expenditures associated with neurological disorders.
View Case

Programmer

Biotechnology · China

WeGreened EB-2 (NIW) approved
Massachusetts 124 days 2022-10-20
The petitioner proposes to develop bioinformatics pipelines for the detection of novel variants and genetic mutations associated with dementia. This work aims to identify new targets for the development of drugs to prevent, postpone, or treat the disease.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from China

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-08-18.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 41 days
Criteria Met 3 / 3
Evidence Types 8

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,816
Success Rate 53.6%
Sustained 2,046
Dismissed 1,674

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in China All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist